Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 64 entries
Sorted by: Best Match Show Resources per page
Cannabis and cardiotoxicity.

Forensic science, medicine, and pathology

Karch SB.
PMID: 25868498
Forensic Sci Med Pathol. 2006 Mar;2(1):13-8. doi: 10.1385/FSMP:2:1:13.

Cannabis is the most commonly consumed illicit drug. It is estimated that 4% of the global population between the ages of 15 and 64 smoked marijuana in 2003. Despite the drug's extreme popularity, reports of cannabis-related stroke and myocardial...

Cite
Karch SB. Cannabis and cardiotoxicity. Forensic Sci Med Pathol. 2006;2(1):13-8doi: 10.1385/FSMP:2:1:13.
Karch, S. B. (2006). Cannabis and cardiotoxicity. Forensic science, medicine, and pathology, 2(1), 13-8. https://doi.org/10.1385/FSMP:2:1:13
Karch, Steven B. "Cannabis and cardiotoxicity." Forensic science, medicine, and pathology vol. 2,1 (2006): 13-8. doi: https://doi.org/10.1385/FSMP:2:1:13
Karch SB. Cannabis and cardiotoxicity. Forensic Sci Med Pathol. 2006 Mar;2(1):13-8. doi: 10.1385/FSMP:2:1:13. PMID: 25868498.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M.
PMID: 17440629
Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73.

Agomelatine, AGRO-100, AIDSVAX gp120 B/E, alfimeprase, aliskiren fumarate, ALVAC vCP1452, alvocidib hydrochloride, ambrisentan, AME-527, AN-0128, apadenoson, ARRY-142886, asenapine maleate, axitinib, azimilide hydrochloride; Belimumab, bevacizumab, biolimus A9, BiovaxID, bryostatin 1; Cannabidiol, celgosivir, CG-1940/CG-8711, CKD-501, collagen-PVP, CpG-10101, CTL-102, CTL-102/CB-1954; D-4F, darusentan,...

Cite
Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(2):153-73
Bayes, M. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(2), 153-73.
Bayes, Miriam. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,2 (2007): 153-73.
Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. PMID: 17440629.
Copy Download .nbib Format: NLM
Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury.

Journal of pain research

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala YJ, Botteman M.
PMID: 23874121
J Pain Res. 2013 Jul 11;6:539-47. doi: 10.2147/JPR.S45966. Print 2013.

BACKGROUND: Management of neuropathic pain (NeP) associated with spinal cord injury (SCI) is difficult. This report presents a systematic literature review and comparison of the efficacy and safety of pharmacologic therapies for treating SCI-associated NeP.METHODS: Medline, Embase, Cochrane, and...

Cite
Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. J Pain Res. 2013;6:539-47doi: 10.2147/JPR.S45966.
Snedecor, S. J., Sudharshan, L., Cappelleri, J. C., Sadosky, A., Desai, P., Jalundhwala, Y. J., & Botteman, M. (2013). Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. Journal of pain research, 6539-47. https://doi.org/10.2147/JPR.S45966
Snedecor, Sonya J, et al. "Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury." Journal of pain research vol. 6 (2013): 539-47. doi: https://doi.org/10.2147/JPR.S45966
Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala YJ, Botteman M. Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. J Pain Res. 2013 Jul 11;6:539-47. doi: 10.2147/JPR.S45966. Print 2013. PMID: 23874121; PMCID: PMC3712802.
Copy Download .nbib Format: NLM
Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study.

CMAJ open

Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Daeninck P, Bolton J, Sareen J, Leong C.
PMID: 30563919
CMAJ Open. 2018 Dec 18;6(4):E637-E642. doi: 10.9778/cmajo.20180109. Print 2018.

BACKGROUND: Pharmaceutically derived cannabinoids are used for several indications, particularly pain management. The extent of their use from a population perspective is unknown; hence, the aim of this study was to evaluate trends in pharmaceutical cannabinoid use in Manitoba.METHODS:...

Cite
Alkabbani W, Marrie RA, Bugden S, et al. Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open. 2018;6(4):E637-E642doi: 10.9778/cmajo.20180109.
Alkabbani, W., Marrie, R. A., Bugden, S., Alessi-Severini, S., Daeninck, P., Bolton, J., Sareen, J., & Leong, C. (2018). Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ open, 6(4), E637-E642. https://doi.org/10.9778/cmajo.20180109
Alkabbani, Wajd, et al. "Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study." CMAJ open vol. 6,4 (2018): E637-E642. doi: https://doi.org/10.9778/cmajo.20180109
Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Daeninck P, Bolton J, Sareen J, Leong C. Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open. 2018 Dec 18;6(4):E637-E642. doi: 10.9778/cmajo.20180109. Print 2018. PMID: 30563919; PMCID: PMC6298870.
Copy Download .nbib Format: NLM
Cannabis (Marijuana) - Effects on Human Performance and Behavior.

Forensic science review

Huestis MA.
PMID: 26256486
Forensic Sci Rev. 2002 Feb;14(1):15-60.

Cannabis is one of the oldest and most commonly abused drugs in the world. Recently, tremendous advances have been made in our understanding of the endogenous cannabinoid system with the identification of cannabinoid receptors, cannabinoid receptor antagonists, endogenous neurotransmitters,...

Cite
Huestis MA. Cannabis (Marijuana) - Effects on Human Performance and Behavior. Forensic Sci Rev. 2002;14(1):15-60
Huestis, M. A. (2002). Cannabis (Marijuana) - Effects on Human Performance and Behavior. Forensic science review, 14(1), 15-60.
Huestis, M A. "Cannabis (Marijuana) - Effects on Human Performance and Behavior." Forensic science review vol. 14,1 (2002): 15-60.
Huestis MA. Cannabis (Marijuana) - Effects on Human Performance and Behavior. Forensic Sci Rev. 2002 Feb;14(1):15-60. PMID: 26256486.
Copy Download .nbib Format: NLM
Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder.

Current addiction reports

Martin EL, McRae-Clark AL.
PMID: 33816054
Curr Addict Rep. 2020 Dec;7:545-552. doi: 10.1007/s40429-020-00342-8. Epub 2020 Nov 09.

PURPOSE OF REVIEW: Cannabis use disorder (CUD) is highly prevalent. Psychotherapy alone is not adequately effective, with few individuals achieving abstinence. Pharmacotherapeutic supplementation may improve efficacy, and the endocannabinoid system presents a target specifically dysregulated by heavy cannabis use....

Cite
Martin EL, McRae-Clark AL. Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. Curr Addict Rep. 2020;7:545-552doi: 10.1007/s40429-020-00342-8.
Martin, E. L., & McRae-Clark, A. L. (2020). Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. Current addiction reports, 7545-552. https://doi.org/10.1007/s40429-020-00342-8
Martin, Erin L, and McRae-Clark, Aimee L. "Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder." Current addiction reports vol. 7 (2020): 545-552. doi: https://doi.org/10.1007/s40429-020-00342-8
Martin EL, McRae-Clark AL. Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. Curr Addict Rep. 2020 Dec;7:545-552. doi: 10.1007/s40429-020-00342-8. Epub 2020 Nov 09. PMID: 33816054; PMCID: PMC8011453.
Copy Download .nbib Format: NLM
Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial.

Brain sciences

Swartwood C, Salottolo K, Madayag R, Bar-Or D.
PMID: 32178232
Brain Sci. 2020 Mar 12;10(3). doi: 10.3390/brainsci10030161.

Delta-9-tetrahydrocannabinol (Δ

Cite
Swartwood C, Salottolo K, Madayag R, et al. Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial. Brain Sci. 2020;10(3)doi: 10.3390/brainsci10030161.
Swartwood, C., Salottolo, K., Madayag, R., & Bar-Or, D. (2020). Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial. Brain sciences, 10(3), . https://doi.org/10.3390/brainsci10030161
Swartwood, Claire, et al. "Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial." Brain sciences vol. 10,3 (2020). doi: https://doi.org/10.3390/brainsci10030161
Swartwood C, Salottolo K, Madayag R, Bar-Or D. Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial. Brain Sci. 2020 Mar 12;10(3). doi: 10.3390/brainsci10030161. PMID: 32178232; PMCID: PMC7139558.
Copy Download .nbib Format: NLM
Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland.

Medical cannabis and cannabinoids

Hupli AMM.
PMID: 34676327
Med Cannabis Cannabinoids. 2018 Nov 23;1(2):112-118. doi: 10.1159/000495307. eCollection 2019 Jan.

This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse...

Cite
Hupli AMM. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Med Cannabis Cannabinoids. 2018;1(2):112-118doi: 10.1159/000495307.
Hupli, A. M. M. (2019). Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Medical cannabis and cannabinoids, 1(2), 112-118. https://doi.org/10.1159/000495307
Hupli, Aleksi Mikael Markunpoika. "Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland." Medical cannabis and cannabinoids vol. 1,2 (2019): 112-118. doi: https://doi.org/10.1159/000495307
Hupli AMM. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Med Cannabis Cannabinoids. 2018 Nov 23;1(2):112-118. doi: 10.1159/000495307. eCollection 2019 Jan. PMID: 34676327; PMCID: PMC8489316.
Copy Download .nbib Format: NLM
A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?.

Cureus

Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Sapkota A, Alfonso M.
PMID: 34567876
Cureus. 2021 Aug 20;13(8):e17332. doi: 10.7759/cureus.17332. eCollection 2021 Aug.

Fibromyalgia syndrome (FMS) is a pain disorder characterized by chronic widespread pain, fatigue, and sleep disturbance, in the absence of any well-defined underlying organic disease. The exact pathophysiology and the mechanism which links different factors related to the disease...

Cite
Khurshid H, Qureshi IA, Jahan N, et al. A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?. Cureus. 2021;13(8):e17332doi: 10.7759/cureus.17332.
Khurshid, H., Qureshi, I. A., Jahan, N., Went, T. R., Sultan, W., Sapkota, A., & Alfonso, M. (2021). A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?. Cureus, 13(8), e17332. https://doi.org/10.7759/cureus.17332
Khurshid, Hajra, et al. "A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?." Cureus vol. 13,8 (2021): e17332. doi: https://doi.org/10.7759/cureus.17332
Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Sapkota A, Alfonso M. A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?. Cureus. 2021 Aug 20;13(8):e17332. doi: 10.7759/cureus.17332. eCollection 2021 Aug. PMID: 34567876; PMCID: PMC8451533.
Copy Download .nbib Format: NLM
THC shows activity against cultured Plasmodium falciparum.

Bioorganic & medicinal chemistry letters

de Sousa ACC, Combrinck JM, Maepa K, Egan TJ.
PMID: 34763083
Bioorg Med Chem Lett. 2021 Dec 15;54:128442. doi: 10.1016/j.bmcl.2021.128442. Epub 2021 Nov 08.

The FDA approved drug Dronabinol was identified in a previous study applying virtual screening using the haemozoin crystal as a target against malaria parasites. The active ingredient of dronabinol is synthetic tetrahydrocannabinol (THC), which is one of the major...

Cite
de Sousa ACC, Combrinck JM, Maepa K, et al. THC shows activity against cultured Plasmodium falciparum. Bioorg Med Chem Lett. 2021;54:128442doi: 10.1016/j.bmcl.2021.128442.
de Sousa, A. C. C., Combrinck, J. M., Maepa, K., & Egan, T. J. (2021). THC shows activity against cultured Plasmodium falciparum. Bioorganic & medicinal chemistry letters, 54128442. https://doi.org/10.1016/j.bmcl.2021.128442
de Sousa, Ana Carolina C, et al. "THC shows activity against cultured Plasmodium falciparum." Bioorganic & medicinal chemistry letters vol. 54 (2021): 128442. doi: https://doi.org/10.1016/j.bmcl.2021.128442
de Sousa ACC, Combrinck JM, Maepa K, Egan TJ. THC shows activity against cultured Plasmodium falciparum. Bioorg Med Chem Lett. 2021 Dec 15;54:128442. doi: 10.1016/j.bmcl.2021.128442. Epub 2021 Nov 08. PMID: 34763083.
Copy Download .nbib Format: NLM
Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative.

American journal of therapeutics

Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA.
PMID: 11854790
Am J Ther. 1995 Oct;2(10):799-805. doi: 10.1097/00045391-199510000-00012.

Spinal-cord-injured patients and the medical literature have increasingly reported anecdotes regarding tetrahydrocannabinol (THC)-induced spasmolysis. These reports motivated this trial of dronabinol, a THC derivative, for the treatment of spasticity in the spinal-cord-injured population. Five made quadriplegic patients were given...

Cite
Kogel RW, Johnson PB, Chintam R, et al. Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative. Am J Ther. 1995;2(10):799-805doi: 10.1097/00045391-199510000-00012.
Kogel, R. W., Johnson, P. B., Chintam, R., Robinson, C. J., & Nemchausky, B. A. (1995). Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative. American journal of therapeutics, 2(10), 799-805. https://doi.org/10.1097/00045391-199510000-00012
Kogel, Robert W., et al. "Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative." American journal of therapeutics vol. 2,10 (1995): 799-805. doi: https://doi.org/10.1097/00045391-199510000-00012
Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA. Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative. Am J Ther. 1995 Oct;2(10):799-805. doi: 10.1097/00045391-199510000-00012. PMID: 11854790.
Copy Download .nbib Format: NLM
[Acute coronary syndrome associated with dronabinol].

Therapie

Revol B, Chittaro C, Frey P, Ferrando S, Guérin F, Pineau-Blondel E, Mallaret M.
PMID: 31351744
Therapie. 2020 May - Jun;75(3):309-311. doi: 10.1016/j.therap.2019.07.001. Epub 2019 Jul 11.

No abstract available.

Cite
Revol B, Chittaro C, Frey P, et al. Syndrome coronarien aigu associé au dronabinol. [Acute coronary syndrome associated with dronabinol]. Therapie. 2019;75(3):309-311doi: 10.1016/j.therap.2019.07.001.
Revol, B., Chittaro, C., Frey, P., Ferrando, S., Guérin, F., Pineau-Blondel, E., & Mallaret, M. (2020). Syndrome coronarien aigu associé au dronabinol. [Acute coronary syndrome associated with dronabinol]. Therapie, 75(3), 309-311. https://doi.org/10.1016/j.therap.2019.07.001
Revol, Bruno, et al. "Syndrome coronarien aigu associé au dronabinol." [Acute coronary syndrome associated with dronabinol]. Therapie vol. 75,3 (2020): 309-311. doi: https://doi.org/10.1016/j.therap.2019.07.001
Revol B, Chittaro C, Frey P, Ferrando S, Guérin F, Pineau-Blondel E, Mallaret M. Syndrome coronarien aigu associé au dronabinol. [Acute coronary syndrome associated with dronabinol]. Therapie. 2020 May - Jun;75(3):309-311. doi: 10.1016/j.therap.2019.07.001. Epub 2019 Jul 11. French. PMID: 31351744.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 64 entries